Treatment of Indolent Non-Hodgkin’s Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The termindolent in describing a non-Hodgkin’s lymphoma (NHL) generally refers to a group of B-cell NHLs composed of predominantly small cells that make up several categories, including follicular lymphoma, small lymphocytic lymphoma, and lymphoma of mucosa-associated lymphoid tissue. Most patients with follicular lymphoma respond to therapy, and the average survival time in large series is approximately 10 years. Patients who achieve a complete remission with initial treatment have an approximately 25% chance of remaining free of disease for 10 years. However, this means that more than 80% of patients will require salvage therapy. Cladribine is a newer purine analogue and is of particular interest because it is resistant to deam-ination by adenosine deaminase. It is cytotoxic to both proliferating and resting lymphocytes, making it an attractive agent for the treatment of indolent NHL. In this review article, we summarize the current treatment approaches for indolent NHL and the results of cladribine monotherapy studies in Japan and cladribine studies in Germany that have focused on a combination therapy with mitoxantrone. Cladribine is a potent inhibitor of DNA repair. The combination of a DNA-damaging agent with an inhibitor of DNA repair constitutes the rationale for combining cladribine with mitoxantrone. A German study has demonstrated that the combination of reduced-dose cladribine and mitoxantrone is a highly active regimen with favorable toxicity profiles. Cladribine is highly effective as a single agent and in combination with mitoxantrone in the treatment of indolent NHL, and its availability broadens the range of therapeutic options for indolent NHL.
Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting —Airlie House, Virginia, November 1997.J Clin Oncol. 1999;17: 3835–3849.PubMed
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin’s lymphoma.N Engl J Med. 1993;329:987–994.CrossRef
Armitage JO, Weisenburger DD. New approach to classifying non- Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project.J Clin Oncol. 1998;16:2780–2795.PubMed
The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma.Blood. 1997;89:3909–3918.
Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.N Engl J Med. 1984;311:1471–1475.PubMed
Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow- up study of patients treated at Stanford University.J Clin Oncol. 1996;14:1282–1290.
Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas.Int J Radiat Oncol Biol Phys. 2001;51:1219–1227.PubMed
Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience.Int J Radiat Oncol Biol Phys. 1984;10:489–497.PubMed
Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ. Case/ control study of the role of splenectomy in chronic lymphocytic leukemia.J Clin Oncol. 1997;15:52–60.PubMed
Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival.J Clin Oncol. 1986;4:1470–1480.PubMed
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833.PubMed
Ghielmini M, Hsu Schmitz S-F, Cogliatti S, et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK Trial [abstract].Blood. 2002;100:161a. Abstract 604.
Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas.J Clin Oncol. 2000;18:1316–1323.PubMed
Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas.J Clin Oncol. 2001;19:3918–3928.PubMed
Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.Semin Oncol. 1999;26(suppl 14):88–96.PubMed
Marcus R, Imrie K, Belch A, et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin’s lymphoma [abstract].Blood. 2003;102:28a. Abstract 87.
Byrd JC, Rai KR, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JEA. The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients [abstract].Blood. 2003;102:273a. Abstract 245.
Rohatiner AZ, Gregory WM, Peterson BA, Smalley RV. A meta- analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma [abstract].Proc Am Soc Clin Oncol. 1998;17:4a. Abstract 11.
Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma.J Clin Oncol. 1997;15:445–450.PubMed
Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood. 1999;94:3325–3333.PubMed
O’Connor OA, Wright J, Moskowitz C, Macgregor-Cortelli B, Straus D, Horse-Grant D. Phase II clinical experience with the pro- teasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphoma [abstract].Proc Am Soc Clin Oncol. 2003;22: 2566. Abstract 2277.
Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.Blood. 1999;94:1840–1847.PubMed
Wierda WG, O’Brien S, Faderl S, et al. Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination [abstract].Blood. 2003;102:100a. Abstract 373.
Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed.Blood. 2000;95:802–806.PubMed
Zucca E, Conconi A, Roggero E, Ascani S, Campo E, Capella C. Non-gastric MALT lymphomas: a survey of 369 European patients: the International Extranodal Lymphoma Study Group (IELSG) [abstract].Ann Oncol. 2000;11:4499. Abstract 4440.
Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphory- lase deficiency: possible role of nucleoside kinase(s).Proc Natl AcadSci USA. 1977;74:5677–5681.CrossRef
Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.N Engl J Med. 1990;322:1117–1121.PubMed
Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the major- ity of patients with hairy cell leukemia.Blood. 1992;80:2203–2209.PubMed
Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.J Clin Oncol. 1993;11:679–689.PubMed
Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.J Clin Oncol. 1995;13:570–574.PubMed
Barton K, Larson RA, O’Brien S, Ratain MJ. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine.J Clin Oncol. 1992;10:1821.PubMed
Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treat- ment of low-grade lymphomas.J Clin Oncol. 1992;10:371–377.PubMed
Hoffman M, Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin’s lymphoma.J Clin Oncol. 1994;12:788–792.PubMed
Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin’s lymphoma.Blood. 1995;86:1710–1716.PubMed
Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group: the Clinical Trial Review Committee of the Japan Clinical Oncology Group.Jpn J Clin Oncol. 1993;23:250–257.PubMed
Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review.J Clin Oncol. 1994;12:2216–2228.PubMed
Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.Blood. 1992;80:587–592.PubMed
O’Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.Blood. 1994;84:733–738.PubMed
Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma [see comments].Blood. 1996;87:906–911.PubMed
Tobinai K, Kobayashi Y, Morishima Y. Prolonged cytopenia and myelodysplastic syndrome after cladribine treatment in relapsed patients with indolent non-Hodgkin’s lymphoma: results of Japanese phase II study [abstract].Proc Am Soc Clin Oncol. 2001;20: 2228b. Abstract 2664.
Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.J Clin Oncol. 1999;17:2454–2460.PubMed
Hickish T, Serafinowski P, Cunningham D, et al. 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.Br J Cancer. 1993;67:139–143.PubMed
Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.Ann Oncol. 1995;6:49–52.PubMed
Liliemark J, Juliusson G Cellular pharmacokinetics of 2-chloro-2-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients.Clin Cancer Res. 1995;1:385–390.PubMed
Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2-deoxyadenosine in humans: alternative routes of administration.J Clin Oncol. 1992;10: 1514–1518.PubMed
Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.J Clin Oncol. 1995;13:989–995.PubMed
Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients.J Clin Oncol. 1997;15:1803–1810.PubMed
Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin’s lymphoma.J Clin Oncol. 1996;14:2139–2144.PubMed
Betticher DC, von Rohr A, Ratschiller D, et al. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin’s lymphoma.J Clin Oncol. 1998;16:850–858.PubMed
Robak T, Gora-Tybor J, Urbanska-Rys H, Krykowski E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin’s lymphoma.Leuk Lymphoma. 1999;32:359–363.PubMed
- Treatment of Indolent Non-Hodgkin’s Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone
International Journal of Hematology
Volume 79, Issue 4 , pp 311-321
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Indolent lymphoma
- Industry Sectors
- Author Affiliations
- 1. Section of Oncology/Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA
- 2. Hematology Division, National Cancer Center Hospital, Tokyo, Japan
- 3. Department of Internal Medicine, Hematology/Oncology, University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Germany